HIVNET/HPTN 023

Safety and Trough Concentrations of Nevirapine Prophylaxis Given Daily, Twice Weekly, or Weekly in Breast-Feeding Infants from Birth to 6 Months

Sponsor: US National Institutes of Health (NIH)

Protocol Summary: HIVNET 023 was a phase I/II, open-label, randomized trial of the safety and trough concentrations of three dosing regimens of nevirapine given as prophylaxis from birth to 24 weeks in breast-feeding infants born to HIV-1–infected mothers. Pregnant women were offered HIV-1 testing to screen for the study. Eligible HIV-1–infected women were enrolled in the study at 30 to 38 weeks of gestation. All women received standardized information based on the current UNAIDS guidelines on breast-feeding. Each enrolled HIV-1–infected pregnant woman was prescribed a single 200-mg oral dose of NVP to self-administer at the onset of labor.

Years: 2000 – 2001

Investigators: Avinash Shetty, MD
Yvonne Maldonado, MD

Locations: Seke North and St. Mary’s CRSs

Comments are closed.